Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged
as a focal point in global nuclear medicine, underscored by their promising applications in …

Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein which is
overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound …

In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have
shown promising results in the diagnosis of cancer and several other diseases, making them …

The recent development of quinoline-based PET tracers that act as fibroblast-activation-
protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is …

Quinoline‐based fibroblast activation protein (FAP) inhibitor (FAPI)‐based positron emission
tomography (PET) imaging and radioligand therapy (RLT) are being investigated for use in a …

Fibroblast activation protein inhibitor (FAPI) is a promising tracer in oncologic positron
emission tomography/computed tomography (PET/CT). Numerous studies have …

Fibroblast activation protein-α (FAP-α) is a type II transmembrane glycoprotein that is
overexpressed in activated fibroblasts such as those in the stroma of tumors or in the fibrotic …

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts of
several tumor entities. The recent development of quinoline-based PET tracers that act as …

Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic
imaging and therapy because they can constitute as much as 90% of a tumor mass. The …

Background In recent years, fibroblast activating protein (FAP), a biomarker overexpressed
by cancer-associated fibroblasts, has emerged as one of the most promising biomarkers in …